1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Jiangsu gdk Biotechnology Co., Ltd. Class A

Jiangsu gdk Biotechnology Co., Ltd. Class A

SSSE:688670
13.43
CNY
+0.09
(+0.67%)
-1.34EPS
2.09BMarket Cap
Oct 30Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
0.96
6.38
3.74
2.61
1.1
0.66
0.92
0.32
Basic EPS, GAAP
-0.46
-0.4
-0.27
1.68
0.79
0.34
-0.58
-0.76
-1.45
-1.34
Free Cash Flow per Basic Share
-0.95
-0.6
-1.07
0.74
-2.69
-1.06
0.22
-1.38
-1.64
- -
Dividend per Share
0.03
0.07
0.05
0.09
0.09
0.37
0.16
0.01
0.01
0.01
Book Value per Share
-0.66
-0.97
-1.17
2.62
11.86
11.85
11.13
10.37
8.92
8.51
Tangible Book Value per Share
-0.96
-1.45
-1.7
2.09
11.39
11.31
10.5
9.72
8.27
7.84
Basic Weighted Avg Shares
70
70
70
92
105
122
122
123
123
123
Sales/Revenue/Turnover
- -
- -
67
589
392
318
135
81
113
39
Operating Margin (%)
- -
- -
-37.41
40.31
36.47
23.15
-32.2
-123.03
-150.35
-398.07
Depreciation Expense
19
21
23
26
28
30
30
30
31
- -
Net Income, GAAP
-33
-28
-19
155
82
42
-71
-94
-178
-165
Effective Tax Rate (%)
- -
- -
- -
26.53
1.83
14.18
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-28.35
26.31
21.02
13.04
-52.75
-115.82
-158.1
-421.3
Working Capital
-328
-370
-393
14
848
649
495
372
114
112
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
28
46
Total Equity
-61
-89
-108
243
1,461
1,460
1,371
1,278
1,099
1,048
Return on Invested Capital (%)
- -
- -
- -
64.83
8.31
2.86
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
66.45
9.16
2.87
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
9.68
2.84
-5.02
-7.07
-15.02
-14.31

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
70
72
78
LT Borrowings
28
28
46
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
123
123
123
Market Capitalization
2,492
2,109
2,087

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
356
308
306
Cash, Cash Equivalents & STI
193
149
190
Accounts Receivable, Net
140
117
71
Inventories
16
33
39
Total Current Liabilities
242
202
194
Payables & Accruals
- -
- -
- -
ST Debt
70
72
78
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
95.13%
-13.97%
Free Cash Flow
- -
-279.85%
18.58%
Net Income, GAAP
- -
-48.95%
90.7%
Sales/Revenue/Turnover
- -
-22.04%
39.7%
Total Cash Common Dividend
- -
40.92%
-22.73%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
-2
36
42
81
2025
3
- -
- -
38
113
2026
1
- -
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.17
-0.16
-0.1
-0.33
-0.76
2025
-0.14
-0.18
- -
-0.75
-1.45
2026
-0.18
-0.23
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jian Hui Zhang
Full Time Employees
390
Sector
Health technology
Industry
Biotechnology
Address
12 Yujin Road Taizhou JS China 225300
IPO Date
Aug 2, 2021
Website
gdkbio.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Jiangsu gdk Biotechnology Co., Ltd. engages in the research, development, production, and sale of human vaccines. The company’s main products include a quadrivalent influenza virus split vaccine for preventing influenza caused by two influenza A strains and two influenza B strains; freeze-dried human rabies vaccines (Vero cell); trivalent inactivated split-virus influenza vaccines; 23-valent and 13-valent pneumococcal polysaccharide conjugate vaccines; and live attenuated varicella and herpes zoster vaccines. Its vaccine portfolio covers the prevention of five major infectious diseases: influenza, rabies, chickenpox, shingles, and pneumonia. Founded in December 2008 and headquartered in Taizhou, China, Jiangsu gdk Biotechnology operates primarily in the domestic Chinese market. The company is a biohigh-tech enterprise integrating scientific research, production, operation, and service of human vaccines, supported by robust technical development capabilities, advanced production and testing equipment, and a scientifically standardized management and quality assurance system. In recent years, the company has focused on expanding its vaccination product pipeline, completing Phase III clinical trials for its freeze-dried human rabies vaccine and progressing clinical trials for pediatric influenza vaccines. It was listed on the Shanghai Stock Exchange Science and Technology Innovation Board (STAR Market) in August 2021. The company continues to develop new vaccine candidates and broaden its infectious disease prevention coverage to meet evolving healthcare demands in China. Its operations do not currently indicate significant international market penetration or major recent strategic partnerships beyond clinical development and product pipeline enhancement.